Histological response is defined as an improvement in the severity of liver inflammation with or without an improvement in fibrosis in patients following treatment for an acute or chronic liver disorder. Histological response occurs in patients with chronic hepatitis C virus (HCV) infection who have had a sustained virological response following treatment with interferon (IFN) therapy and in a percentage of nonresponders. Continuing IFN long term as maintenance therapy has been shown to prevent histological progression in patients who had both a marked decline in serum HCV RNA level during treatment and a histological response on repeat histological analysis. Prospective controlled trials are currently evaluating the benefits of low-dose maintenance therapy with pegylated IFN in HCV patients who have failed to achieve sustained virological response. In the future, the development of serum markers of fibrosis may allow for monitoring of hepatic fibrosis and histological response to therapy without the need to perform repeat liver biopsy.
KEYWORDS
Liver biopsy - peginterferon - fibrosis - cirrhosis - treatment
REFERENCES
-
1
Lindsay K L, Trepo C, Heintges T et al..
A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Hepatology.
2001;
34
395-403
-
2
Zeuzem S, Feinman S V, Rasenack J Z et al..
Peginterferon Alfa-2a in patients with chronic hepatitis C.
N Engl J Med.
2000;
343
1666-1672
-
3
Manns M P, McHutchison J, Gordon S et al..
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet.
2001;
358
958-965
-
4
Fried M W, Shiffman M L, Reddy K R et al..
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med.
2002;
347
975-982
-
5
Poynard T, Bedossa P, Opolon P.
Natural history and prognostic factors for chronic hepatitis C.
Lancet.
1997;
349
825-832
-
6
Tong M J, el-Farra N S, Reikes A R, Co R L.
Clinical outcomes after transfusion-associated hepatitis C.
N Engl J Med.
1995;
332
1463-1466
-
7
Myers R P, Hilsden R J, Lee S S.
Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C.
J Viral Hepat.
2001;
8
249-255
-
8
Saadeh S, Cammell G, Carey W D et al..
The role of liver biopsy in chronic hepatitis C.
Hepatology.
2001;
33
196-200
-
9
Knodell R G, Ishak K G, Black W C.
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.
Hepatology.
1981;
1
431-435
-
10
Scheuer P.
Classification of chronic viral hepatitis. A need for reassessment.
J Hepatol.
1991;
13
372-374
-
11
Ishak K, Baptista A, Bianchi L et al..
Histological grading and staging of chronic hepatitis.
J Hepatol.
1995;
22
696-699
-
12
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C .
The French METAVIR Cooperative Study Group.
Hepatology.
1994;
20
15-20
-
13
Heathcote E J, Shiffman M L, Cooksley W G et al..
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med.
2000;
343
1673-1680
-
14
Reddy K R, Wright T L, Pockros P J et al..
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Hepatology.
2001;
33
433-438
-
15
McHutchison J G, Gordon S C, Schiff E R et al..
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med.
1998;
339
1485-1492
-
16
Poynard T, Marcellin P, Lee S S et al..
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet.
1998;
352
1426-1432
-
17
Shiffman M L, Hofmann C M, Thompson E B et al..
Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
Hepatology.
1997;
26
780-785
-
18
Bodenheimer Jr H C, Lindsay K L, Davis G L et al..
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.
Hepatology.
1997;
26
473-477
-
19
Neuman M, Benhamou J-P, Bourliere M et al..
Transforming growth factor levels in chronic hepatitis C reflect the degree of fibrosis: role of therapy with pegylated interferon in reducing fibrosis score.
Hepatology.
2001;
34
426A
-
20
Poynard T, McHutchison J, Manns M et al..
Impact of pegylated interferon alfa-2b plus ribavirin on liver fibrosis in patients with chronic hepatitis C.
Gastroenterology.
2002;
122
1303-1313
-
21
Arthur M J.
Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.
Gastroenterology.
2002;
122
1525-1528
-
22
Shiffman M L, Hofmann C M, Contos M J et al..
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.
Gastroenterology.
1999;
117
1164-1172
-
23
Di Bisceglie A M, Bonkovsky H L, Deinstag J L et al..
Design of the HALT-C trial (hepatitis C antiviral long-term treatment to prevent cirrhosis).
Gastroenterology.
2000;
118 (suppl 2)
1435A
-
24
Romagnuolo J, Jhangri G S, Jewell L D, Bain V G.
Predicting the liver histology in chronic hepatitis C: how good is the clinician?.
Am J Gastroenterol.
2001;
96
3165-3174
-
25
Pohl A, Behling C, Oliver D et al..
Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection.
Am J Gastroenterol.
2001;
96
3142-3146
-
26
Patel K, Gordon S C, Oh E, Smith K, McHutchison J G.
A non-invasive panel of serum fibrosis markers can reliably differentiate hepatitis C patients with minimal fibrosis from those with fibrosis stages F2-F4.
Hepatology.
2002;
36
355A
-
27
Dayhoff J E, DeLeo J M.
Artificial neural networks: opening the black box.
Cancer.
2001;
91
1615-1635
-
28
Haydon G H, Jalan R, Ala-Korpela M et al..
Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors.
J Viral Hepat.
1998;
5
255-264
-
29
Yamada M, Fukuda Y, Koyama Y et al..
Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.
J Gastroenterol Hepatol.
1996;
11
646-651
-
30
Ninomiya T, Yoon S, Hayashi Y et al..
Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system.
J Gastroenterol Hepatol.
1998;
13
68-74
-
31
Fabris P, Marranconi F, Bozzola L et al..
Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
J Gastroenterol.
1999;
34
345-350
-
32
Itoh Y, Okanoue T, Ohnishi N et al..
Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection.
Am J Gastroenterol.
1999;
94
1332-1340
-
33
Mitsuda A, Suou T, Ikuta Y, Kawasaki H.
Changes in serum tissue inhibitor or matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
J Hepatol.
2000;
32
666-672
-
34
Kojima H, Hongo Y, Harada H et al..
Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.
J Gastroenterol Hepatol.
2001;
16
1015-1021
-
35
Leroy V, De Traversay C, Barnoud R et al..
Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.
J Hepatol.
2001;
35
120-126
-
36
Serejo F, Costa A, Oliveira A G et al..
Alfa-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Dig Dis Sci.
2001;
46
1684-1689
-
37
Ueno T, Ide T, Hashimoto O et al..
Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers.
Hepatogastroenterology.
2001;
48
1124-1128
-
38
George J.
Biochemical markers of hepatic fibrogenesis: single measurements are not reliable enough to replace liver biopsy.
J Gastroenterol Hepatol.
2000;
15
819-821
-
39
Kanzler S, Baumann M, Schirmacher P et al..
Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta.
J Viral Hepat.
2001;
8
430-437
-
40
Neuman M, Benhamou J, Akremi R et al..
Serum tumor necrosis factor level in chronic hepatitis C.
J Hepatol.
2001;
34
108-109
Samuel S LeeM.D.
Faculty of Medicine, University of Calgary
3330 Hospital Drive NW, Calgary, AB
T2N 4N1, Canada
Email: samlee@ucalgary.ca
